Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (CLVSF)
OTHER OTC:CLVSF
Top Page
CellaVision AB (CLVSF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$481.11M
Dividend Yield1.38%
Average Volume (3M)0.00
Price to Earnings (P/E)28.1
Beta (1Y)0.94
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees228
SectorHealthcare
Sector Strength41
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.18
Shares Outstanding23,851,547
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio3.75
Price to Book (P/B)5.54
Price to Sales (P/S)0.00
P/FCF Ratio70.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CellaVision AB Business Overview & Revenue Model
Company DescriptionCellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
How the Company Makes Money
CellaVision AB Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q3-2024)
| % Change Since: 1.63%|
Next Earnings Date:Jul 18, 2025
Earnings Call Sentiment Neutral
The call reflected a mix of strong growth in EMEA and positive strategic developments, offset by challenges in the Americas and APAC regions, and increased expenses. Despite some regional and financial fluctuations, the company's strategic initiatives and growth in core areas provide a balanced outlook.Q3-2024 Updates
Positive Updates
Strong Sales in EMEA
EMEA experienced very strong growth across multiple markets and product groups, achieving an all-time high in sales even after accounting for early orders.
Organic Growth and Improved Gross Margin
The company reported an organic growth of 9% and an increase in gross margin from 66% to 68%.
Strategic Partnership with Sysmex
Continued development of strategic partnership with Sysmex, including joint training and marketing activities.
Progress in Clinical Validation
Progress according to plan on clinical validations for the bone marrow product, with a launch expected in 2025.
Reagent Growth
Reagents showed an 11% growth, with significant performance in EMEA.
Negative Updates
Decline in Americas
Sales declined in the Americas due to political uncertainties affecting hospital order placements.
APAC Revenue Fluctuations
APAC experienced fluctuations, with no shipments to China this quarter, resulting in a revenue drop from SEK 22 million to SEK 12 million.
Increased R&D Expenses
R&D expenses rose, driven by the execution of clinical trials and the maturation of multiple programs.
Cash Flow Impacted by Working Capital
Cash flow appeared weaker than the comparable quarter, affected by working capital changes, particularly in accounts receivable and inventory.
Company Guidance
During the Q3 2024 earnings call for CEVI.ST, the executives provided guidance highlighting an organic growth of 9%, achieving a revenue of SEK 179 million compared to SEK 168 million from the previous year. The EBITDA margin was reported at 27%, equivalent to SEK 49 million. The company experienced strong sales in the EMEA region with a 50% sequential growth in instrument sales, while sales declined by 20% in the Americas due to political uncertainties affecting hospital order placements. APAC showed fluctuations, with a notable absence of shipments to China this quarter. Gross margins improved from 66% to 68%, largely driven by the implementation of price increases. Additionally, the company is progressing on strategic partnerships and clinical validation, aiming to launch a bone marrow product with a CE Mark in Europe by 2025. R&D expenses constituted 22% of sales, reflecting investments in maturing development programs, including advancements in FPM technology. The cash flow for the quarter stood at SEK 16 million, with inventory levels gradually decreasing towards normal levels.CellaVision AB Financial Statement Overview
Summary
CellaVision AB exhibits strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion. Overall, CellaVision is well-positioned in the Medical Devices industry.Income Statement
CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.85
Very Positive
Balance Sheet
The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.78
Positive
Cash Flow
CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.72
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 747.94M | 723.22M | 677.29M | 639.34M | 565.55M | 471.44M | Gross Profit |
| 512.22M | 487.07M | 463.04M | 438.32M | 392.30M | 313.04M | EBIT |
| 195.98M | 177.68M | 167.05M | 158.27M | 162.73M | 110.27M | EBITDA |
| 236.47M | 219.75M | 207.25M | 190.87M | 193.60M | 124.60M | Net Income Common Stockholders |
| 152.12M | 140.72M | 130.31M | 118.33M | 125.34M | 89.48M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 182.32M | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M | Total Assets |
| 1.04B | 1.01B | 928.71M | 891.75M | 825.21M | 668.02M | Total Debt |
| 22.96M | 26.85M | 64.70M | 102.50M | 136.65M | 132.78M | Net Debt |
| -159.36M | -122.58M | -56.94M | -5.56M | 6.37M | 30.52M | Total Liabilities |
| 205.34M | 196.16M | 212.32M | 250.12M | 281.93M | 238.41M | Stockholders Equity |
| 838.53M | 815.73M | 716.39M | 641.63M | 543.28M | 429.62M |
| Cash Flow | Free Cash Flow | ||||
| 66.26M | 120.69M | 109.96M | 67.85M | 75.41M | 37.47M | Operating Cash Flow |
| 188.51M | 198.44M | 196.44M | 137.28M | 159.72M | 71.12M | Investing Cash Flow |
| -80.37M | -76.01M | -85.53M | -70.01M | -84.34M | -34.96M | Financing Cash Flow |
| -88.45M | -95.09M | -97.04M | -90.41M | -48.48M | -35.22M |
CellaVision AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| $481.11M | 28.09 | 18.49% | 1.38% | ― | ― | ||
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
| €104.94M | 35.92 | 10.11% | ― | ― | ― | ||
| €612.72M | 73.39 | 1.21% | 0.58% | ― | ― | ||
| €200.18M | ― | -40.15% | ― | ― | ― | ||
| €106.09M | ― | -42.24% | ― | ― | ― | ||
| kr7.75B | 57.14 | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CLVSF
CellaVision AB
16.82
-7.95
-32.10%
DE:24C
C-Rad AB Class B
2.98
-0.84
-21.99%
DE:7XY
Swedencare AB
3.75
-1.64
-30.43%
DE:6Y4
Vicore Pharma Holding AB
0.84
-1.04
-55.32%
DE:6XP
Xspray Pharma AB
2.84
-3.73
-56.77%
SE:SUS
Surgical Science Sweden AB
158.00
19.10
13.75%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.